HYDRATED CRYSTALLINE FORMS OF N-[3-FLUORO-4-({6-(METHYLOXY)-7-[(3-MORPHOLIN-4-YLPROPYL)OXY]-QUINOLIN-4-YL}OXY)PHENYL]-N-(4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE
This invention relates crystalline hydrates of N-[3-fluoro-4-({6-(methyloxy)-7-[(3- morpholin-4-ylpropyl)oxy]quinolin-4-yl }oxy)phenyl]-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, Compound (I). The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline hydrate of Compound (I) and a pharmaceutically acceptable excipient.